Enanta Pharmaceuticals is a clinical stage biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and immunological diseases. Enanta’s research and development efforts include programs in the following disease areas: respiratory syncytial virus (RSV), SARS-CoV-2 (C0VID-19) and hepatitis B Virus (HBV) and chronic spontaneous urticaria (CSU).
Volume:
Minimum 15 minutes delayed. Source:
Recent Press Releases
September 26, 2024
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
September 3, 2024
Enanta Pharmaceuticals to Participate in Investor Conferences in September
Upcoming Events
More events are coming soon.
- Print Page Print Page
- Email Alerts Email Alerts
- RSS Feeds RSS Feeds
- Contact IR Contact IR